Core Insights - Coya Therapeutics, Inc. is developing COYA 303, a proprietary combination of LD-IL-2 and GLP-1RA, aimed at treating diseases like Alzheimer's Disease driven by chronic inflammation [1][2][3] - The initial results from an in vivo study indicate that COYA 303 significantly reduces neuroinflammation and enhances regulatory T cell (Treg) function, suggesting its potential in neurodegenerative conditions [2][3][6] - The company is currently conducting further experimental cohorts to evaluate modified treatment protocols and the timing of treatment initiation [4] Company Overview - Coya Therapeutics is a clinical-stage biotechnology company focused on enhancing Treg function to target systemic and neuroinflammation [5][7] - The company believes that Treg dysfunction is a key factor in various diseases, including neurodegenerative and autoimmune conditions [5][7] - Coya's therapeutic pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy [7] Study Findings - COYA 303 demonstrated significant systemic and central immunomodulatory effects, including enhanced Treg numbers and function, reduced activated myeloid cells, and attenuation of neuroinflammation in the cortex and hippocampus [6] - The findings from the first cohort of the study align with previous in vitro results, reinforcing the potential of COYA 303 in modulating inflammatory pathways associated with Alzheimer's Disease [1][3][6] - The CEO of Coya highlighted the growing interest in GLP-1 receptor agonists as potential therapies beyond metabolic diseases, positioning COYA 303 as a unique approach to address neuroinflammation [5]

Core Insights - Coya Therapeutics is positioned for a transformative year in 2025 with FDA clearance of its first IND and the initiation of a pivotal ALS trial [3][6] - The company is focused on developing Treg-modulating therapies to address ALS and other neurodegenerative diseases [4][6] Company Overview - Coya Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Houston, TX, specializing in treatments that target systemic inflammation and neuroinflammation through regulatory T cells (Tregs) [4][6] - The company’s pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy [5][6] Recent Developments - The FDA accepted the IND application for COYA 302 in ALS, allowing the start of a Phase 2 clinical trial [6] - Strategic partnerships, notably with Dr. Reddy's Laboratories, provide financial support and expertise in manufacturing and commercialization [6] Future Plans - Coya plans to expand its pipeline beyond ALS, with an IND filing for frontotemporal dementia expected in late 2025 [6] - Key upcoming milestones include the initiation of the ALS trial, data readouts for frontotemporal dementia, and new preclinical results across multiple programs [6]

Core Viewpoint - Coya Therapeutics, Inc. is actively engaging with investors through participation in two upcoming conferences, highlighting its focus on developing biologics for neurodegenerative disorders [1][2]. Company Overview - Coya Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, TX, specializing in treatments that enhance regulatory T cell (Treg) function to address systemic inflammation and neuroinflammation [4]. - The company’s investigational product pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs [5]. Upcoming Events - Coya will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 10 am ET, with a presentation by CEO Arun Swaminathan [2]. - The company will also participate in the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, 2025, where management will be available for one-on-one meetings [2]. Webcast Information - Live and archived webcasts of the presentations will be accessible on the company's website under the Investor Relations section, with replays available for 90 days [3].